Skip to content

The Nori Health App

The Nori Health App: (Pilot) Randomized Controlled Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05474742
Enrollment
50
Registered
2022-07-26
Start date
2022-04-25
Completion date
2022-09-01
Last updated
2023-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease, IBD, Ulcerative Colitis

Keywords

Randomized Controlled Trial, Pilot, Qualitative component

Brief summary

A multicenter, randomized controlled trial with an embedded pilot and qualitative component to investigate the effects of the Nori Health app.

Detailed description

RATIONALE Inflammatory bowel disease (IBD) is an umbrella term used to describe diseases that involve chronic inflammation of the gastrointestinal tract. Although progress in treatment has been made over the past two decades, IBD continues to profoundly affect patients' quality of life. Since patients with IBD have to deal with their disease's complex and unpredictable nature 24 hours a day, it is important that they have access to self-management support outside the hospital. Nori Health aims to provide this support with an app that consists of an artificial intelligence-driven chatbot and 6-week education program. OBJECTIVES The primary objective is to investigate whether use of the Nori Health app improves the level of patient activation for self-management in patients with IBD by comparing an intervention and (waiting-list) control group at 6 weeks after randomization. Secondary objectives are: * To investigate whether there are any differences between the intervention and control group in the level of patient activation for self-management at 12 and 20 weeks after randomization; * To investigate whether there are any differences between the intervention and control group in the level of disease control at 6, 12 and 20 weeks after randomization; * To investigate whether there are any differences between the intervention and control group in quality of life at 6, 12 and 20 weeks after randomization; * To investigate whether there are any differences between the intervention and control group in healthcare utilization at 6, 12 and 20 weeks after randomization; * To investigate intervention fidelity at 6, 12 and 20 weeks after randomization; * To explore the experiences of patients with IBD with use of the Nori Health app and their views on its pros and cons. STUDY DESIGN A multicenter, randomized controlled trial with an embedded pilot and qualitative component. STUDY POPULATION Patients with IBD are eligible for participation if they: * Are aged \>18 years; * Are able to read and write the Dutch language; * Are in the possession of a tablet or smartphone with WiFi connection. Excluded are those with cognitive impairments or who are already familiar with use of the Nori Health app. STUDY INTERVENTION Participants are randomized in a 1:1 ratio to the intervention or control group. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention. Standard IBD care continues unchanged. After study completion, participants in the control group also receive access to the Nori Health app for a 6-month period. STUDY PARAMETERS The level of patient activation for self-management is assessed using the patient activation measure. The IBD control questionnaire and EQ-5D are used to assess respectively the level of disease control and quality of life. Healthcare utilization is assessed with 5 close-ended questions. System data is used to assess intervention fidelity. Experiences of patients with IBD with use of the Nori Health app and their views on its pros and cons are explored by performing individual, semi-structured, telephonic interviews.

Interventions

OTHERThe Nori Health app

The Nori Health app consist of a chatbot that instantly answers questions about topics relevant to patients with IBD and 6-week education program. The chatbot is driven by artificial intelligence and armed with state of the art scientific literature to offer to the right information to the right person at the right time. The education program is offered during the first six weeks of use. The Nori Health app then actively offers information on four fixed topics and two topics to a participant's choosing (i.e. low energy, pain, stress, mental health, hydration, exercising). It is expected from participants that they respond to this by having approximately five chat conversations of five minutes per week. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention.

Sponsors

Elisabeth-TweeSteden Ziekenhuis
CollaboratorOTHER
Radboud University Medical Center
CollaboratorOTHER
UMC Utrecht
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients with IBD are eligible for participation if they: * Are aged \>18 years; * Are able to read and write the Dutch language; * Are in the possession of a tablet or smartphone with WiFi connection. Excluded are those with cognitive impairments or who are already familiar with use of the Nori Health app.

Design outcomes

Primary

MeasureTime frameDescription
Patient Activation Measure (PAM)6 weeks follow-upMeasure of patient activation for self-management. Scale from 0 to 100, higher scores mean a higher level of patient activation for self-management (=better outcome).

Secondary

MeasureTime frameDescription
Patient Activation Measure (PAM)12 and 20 weeks follow-upMeasure of patient activation for self-management. Scale from 0 to 100, higher scores mean a higher level of patient activation for self-management (=better outcome).
Inflammatory Bowel Disease (IBD)-control questionnaire6, 12 and 20 weeks follow-upMeasure of disease control. Scale from 0 to 16, higher scores mean a higher level of disease control (=better outcome).
EuroQol-5 dimension questionnaire (EQ-5D)6, 12 and 20 weeks follow-upMeasure of quality of life. Scale from 0 to 100, higher scores mean a higher quality of life (=better outcome).
Healthcare utilization6, 12 and 20 weeks follow-upBrief questionnaire with 5 close-ended questions on healthcare utilizatio, using a nominal scale (e.g., yes/no).

Other

MeasureTime frameDescription
Interviews6-20 weeks follow-upExperiences of patients with IBD with use of the Nori Health app and their views on its pros and cons.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026